Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-10

FDA Approved: NEOSTIGMINE METHYLSULFATE — Supplemental Application (BE Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for NEOSTIGMINE METHYLSULFATE from BE Pharmaceuticals Inc., updating the approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Neostigmine Methylsulfate (neostigmine methylsulfate)

Snippet

SUPPL AP for NEOSTIGMINE METHYLSULFATE (NEOSTIGMINE METHYLSULFATE)